Form 4: Spero Therapeutics Director Scott Thomas Jackson Granted 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director Scott Thomas Jackson was granted 20,000 Restricted Stock Units (RSUs) on June 12, 2025, as part of his compensation.

Summary

• Scott Thomas Jackson, a Director of Spero Therapeutics, Inc. (SPRO), acquired 20,000 shares of common stock on June 12, 2025.
• These shares were granted as Restricted Stock Units (RSUs) at a price of $0 per unit.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Jackson's continued service to the company.
• Following this transaction, Mr. Jackson beneficially owns 75,000 shares of Spero Therapeutics common stock.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of alignment between management and shareholders, incentivizing long-term commitment and performance. It's a standard compensation practice, indicating stability rather than a significant new development.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Scott Thomas Jackson aligns his interests with those of shareholders, as the value of his compensation is tied to the company's future stock performance.
• The vesting schedule, contingent on continued service, incentivizes long-term commitment and stability in the company's leadership.

Risks

• The value of the granted RSUs is subject to the future market price of Spero Therapeutics' common stock, meaning the actual compensation realized by the director could be lower if the stock price declines.
• The vesting of RSUs is contingent on continued service, meaning the director would forfeit the unvested units if their service terminates before the vesting date.

Future Outlook

NA

Industry Context

This RSU grant is a standard form of equity compensation for directors in the biotechnology and pharmaceutical industry, aiming to align executive and board member interests with long-term shareholder value. It reflects common practices for retaining and incentivizing leadership in growth-oriented companies like Spero Therapeutics.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common practice in the U.S. biotechnology and pharmaceutical sectors, aligning with compensation strategies seen at comparable companies such as Moderna (MRNA), BioNTech (BNTX), or Gilead Sciences (GILD), which frequently use equity awards to incentivize long-term performance and retention.
• The vesting schedule, tied to continued service, is a standard mechanism to ensure board member commitment, similar to governance practices observed across the S&P 500 where equity compensation often includes service-based vesting conditions.
• The $0 acquisition price for RSUs is typical for grants where the value is derived from the underlying stock's market price upon vesting, a method widely adopted in public companies to provide performance-linked compensation without requiring an upfront cash outlay from the recipient.

Corporate Governance

Related Party Transactions

• The grant of 20,000 Restricted Stock Units (RSUs) to Scott Thomas Jackson, a Director of Spero Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the value of his compensation is directly tied to the company's stock performance. This incentivizes decisions that could benefit long-term stock appreciation.
• Employees: While not directly impacting general employees, the stability and incentivization of board members can contribute to overall company stability and strategic direction, indirectly benefiting employees.

Next Steps

• The 20,000 Restricted Stock Units (RSUs) are scheduled to vest on June 12, 2026, contingent upon Director Scott Thomas Jackson's continued service.

Key Dates

Recommendation

Keywords

Spero Therapeutics, SPRO, Form 4, SEC filing, Restricted Stock Units, RSU, insider transaction, director compensation, equity grant, beneficial ownership